Cancer Trials: US FDA Debuts Framework For Patient-Reported Tolerability Assessments

The agency wants sponsors to start with three core symptoms common across cancer therapeutics and then add more treatment-related adverse events from item libraries based on a drug’s mechanism of action and other factors.